| Argenx (ARGX) Upgraded to Buy: Here's Why |
Argenx (ARGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-12 17:05:51 |
Czytaj oryginał (ang.) |
| Argenx Q1 Earnings: Less Than Perfect Report Gets Punished |
Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the Medicare redesign. Underlying demand was strong across the globe, and Vyvgart looks well positioned for continued growth, which should be helped by the approval of the PFS and international indication expansion. |
seekingalpha.com |
2025-05-09 12:02:18 |
Czytaj oryginał (ang.) |
| argenx SE (ARGX) Q1 2025 Earnings Call Transcript |
argenx SE (NASDAQ:ARGX ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Vikram Purohit - Morgan Stanley Rajan Sharma - Goldman Sachs James Gordon - JPMorgan Derek Archila - Wells Fargo Yaron Werber - TD Cowen Victor Floch - BNP Paribas Nat Charoensook - Leerink Partners Amy Li - Jefferies Charles Pitman-King - Barclays Myles Minter - William Blair Suzanne van Voorthuizen - Kempen Yatin Suneja - Guggenheim Andy Chen - Wolfe Research David Nierengarten - Wedbush Securities Gavin Clark-Gartner - Evercore ISI Samantha Semenkow - Citi Leland Gershell - Oppenheimer Joel Beatty - Baird Xian Deng - UBS Operator Good morning. My name is Rob, and I will be your conference operator today. |
seekingalpha.com |
2025-05-09 00:16:03 |
Czytaj oryginał (ang.) |
| Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble |
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors. |
investors.com |
2025-05-08 12:55:08 |
Czytaj oryginał (ang.) |
| argenx Reports First Quarter 2025 Financial Results and Provides Business Update |
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. “We continue to execute on our bold innovation agenda, guided by our ‘Vision 2030' to reach 50,000 patients across 10 labeled indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. |
globenewswire.com |
2025-05-08 05:00:00 |
Czytaj oryginał (ang.) |
| AZN or ARGX: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-05-06 16:46:05 |
Czytaj oryginał (ang.) |
| argenx to Present at BofA Securities 2025 Health Care Conference |
May 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT. |
globenewswire.com |
2025-05-06 05:00:00 |
Czytaj oryginał (ang.) |
| argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 |
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. |
globenewswire.com |
2025-05-01 05:00:00 |
Czytaj oryginał (ang.) |
| Argenx Stock Extends Rally In A Base As Earnings Loom |
Argenx stock is rising Wednesday as the major indexes sell off. The autoimmune disease treatment stock is climbing in an early-stage base. |
investors.com |
2025-04-30 17:06:11 |
Czytaj oryginał (ang.) |
| argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. “Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. |
globenewswire.com |
2025-04-28 05:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Argenx (ARGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-24 14:55:39 |
Czytaj oryginał (ang.) |
| JAZZ vs. ARGX: Which Stock Is the Better Value Option? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-04-17 16:40:36 |
Czytaj oryginał (ang.) |
| Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? |
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-04-15 13:10:37 |
Czytaj oryginał (ang.) |
| FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting |
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). |
benzinga.com |
2025-04-11 21:41:52 |
Czytaj oryginał (ang.) |
| argenx Announces Annual General Meeting of Shareholders on May 27, 2025 |
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. |
globenewswire.com |
2025-04-11 20:01:00 |
Czytaj oryginał (ang.) |
| US FDA approves syringe version of Argenx's immune disorder drug |
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday. |
reuters.com |
2025-04-10 21:59:17 |
Czytaj oryginał (ang.) |
| argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy |
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go' or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025, 11:45 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART® Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). “Today's FDA approval provides a new self-injection option across both approved indications in the U.S. that is designed for patients who seek more independence with their treatment,” said Luc Truyen M.D. |
globenewswire.com |
2025-04-10 21:47:00 |
Czytaj oryginał (ang.) |
| argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP |
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo's durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan April 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of 15 abstracts, including an oral presentation, at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9, 2025 in San Diego, CA. The presentations showcase long-term data of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile. |
globenewswire.com |
2025-04-08 05:00:00 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's March 2025 New Analysts |
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl. |
seekingalpha.com |
2025-04-04 18:30:59 |
Czytaj oryginał (ang.) |
| JAZZ or ARGX: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-03-31 16:45:42 |
Czytaj oryginał (ang.) |